Clinical and economic impact of HeartLogic™ compared with standard care in heart failure patients

Roderick W Treskes1, Monika Beles2, Maria-Luce Caputo3

  • 1Department of Cardiology, Leiden University Medical Centre, Leiden, The Netherlands.

ESC Heart Failure
|February 23, 2021
PubMed

Insights

Activating the HeartLogic™ algorithm for heart failure (HF) patients significantly reduced HF hospitalizations by 74% within one year. This remote monitoring approach also demonstrated notable health economic benefits.

Area of Science:

  • Cardiology
  • Medical Devices
  • Health Informatics

Background:

  • Heart failure (HF) decompensation leads to frequent hospitalizations.
  • Early detection of impending decompensation is crucial for managing HF patients.
  • The HeartLogic™ algorithm offers novel remote monitoring capabilities for HF patients with implantable devices.

Purpose of the Study:

  • To evaluate the effectiveness of the HeartLogic™ algorithm in reducing hospital admissions for decompensated heart failure.
  • To compare HF hospitalization rates in the year before and after HeartLogic™ algorithm activation.

Main Methods:

  • A multicentre, non-blinded, single-arm trial with historical comparison was conducted.
  • 74 eligible heart failure patients with compatible implantable devices were included.
  • HF events and hospitalizations were compared between a 1-year pre-activation and a 1-year post-activation period.

Main Results:

  • Total heart failure hospitalizations decreased from 27 to 7 (P=0.003) post-activation.
  • The number of patients hospitalized for HF declined from 21 to 7 (P=0.005).
  • Hospitalization length of stay reduced from an average of 16 to 7 days (P=0.079), with significant health economic benefits observed.

Conclusions:

  • Activation of the HeartLogic™ algorithm significantly reduces hospitalizations for decompensated heart failure.
  • The algorithm facilitates remote monitoring, leading to improved patient outcomes and health economic benefits.
  • These findings support the integration of advanced algorithmic monitoring in heart failure management.
Abstract

Related Concept Videos

Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
88
Heart Failure III: Clinical Manifestations01:26

Heart Failure III: Clinical Manifestations

Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
148
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
553
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
666
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
210
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
130